Your browser doesn't support javascript.
loading
Patient characteristics associated with delayed time to adjuvant chemotherapy among women treated for stage I-IIIA breast cancer.
Bhimani, Jenna; O'Connell, Kelli; Persaud, Sonia; Blinder, Victoria; Burganowski, Rachael; Ergas, Isaac J; Foley, Marilyn J; Gallagher, Grace B; Griggs, Jennifer J; Heon, Narre; Kolevska, Tatjana; Kotsurovskyy, Yuriy; Kroenke, Candyce H; Laurent, Cecile A; Liu, Raymond; Nakata, Kanichi G; Rivera, Donna R; Roh, Janise M; Tabatabai, Sara; Valice, Emily; Bandera, Elisa V; Bowles, Erin J Aiello; Kushi, Lawrence H; Kantor, Elizabeth D.
Afiliación
  • Bhimani J; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • O'Connell K; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Persaud S; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Blinder V; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Burganowski R; Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA.
  • Ergas IJ; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
  • Foley MJ; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
  • Gallagher GB; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Griggs JJ; Department of Medicine, Division of Hematology/Oncology and Department of Health Management and Policy, University of Michigan, Ann Arbor, Michigan, USA.
  • Heon N; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Kolevska T; Department of Oncology, Kaiser Permanente Medical Center, Vallejo, California, USA.
  • Kotsurovskyy Y; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Kroenke CH; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
  • Laurent CA; Kaiser Permanente School of Medicine, Pasadena, California, USA.
  • Liu R; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
  • Nakata KG; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
  • Rivera DR; San Francisco Medical Center, Kaiser Permanente Northern California, San Francisco, California, USA.
  • Roh JM; Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA.
  • Tabatabai S; Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, Maryland, USA.
  • Valice E; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
  • Bandera EV; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Bowles EJA; Division of Research, Kaiser Permanente Northern California, Oakland, California, USA.
  • Kushi LH; Cancer Epidemiology and Health Outcomes, Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA.
  • Kantor ED; Kaiser Permanente Washington Health Research Institute, Kaiser Permanente Washington, Seattle, Washington, USA.
Int J Cancer ; 155(9): 1577-1592, 2024 Nov 01.
Article en En | MEDLINE | ID: mdl-38970396
ABSTRACT
For patients with breast cancer, delays in chemotherapy initiation have been adversely associated with recurrence and survival. We evaluated patient-level factors associated with delayed chemotherapy initiation, from both diagnosis and surgery, in a community-based cohort of women with early-stage breast cancer. For the Optimal Breast Cancer Chemotherapy Dosing study, we identified a cohort of 34,109 women diagnosed with stage I-IIIA breast cancer at two U.S. integrated healthcare delivery systems between 2004 and 2019. We used logistic regression to calculate odds ratios (OR) and 95% confidence intervals (CI) to identify patient factors associated with delays in chemotherapy initiation after diagnosis (≥90 days) and surgery (≥60 days). Among 10,968 women receiving adjuvant chemotherapy, 21.1% experienced delays in chemotherapy initiation after diagnosis and 21.3% after surgery. Older age, non-Hispanic Black and Hispanic race and ethnicity, and ER+ and/or PR+ disease were associated with increased likelihood of delays to chemotherapy initiation after diagnosis and surgery. People diagnosed in 2012-2019 (vs. 2005-2011), with a higher grade and larger tumor size were less likely to experience delays. Other factors were associated with a higher likelihood of delays specifically from diagnosis (earlier stage, mastectomy vs. breast-conserving surgery), or surgery (higher comorbidity, increased nodal number). Women diagnosed with breast cancer who were at highest risk of progression and recurrence were less likely to experience delays in chemotherapy initiation after diagnosis and surgery. Understanding reasons for chemotherapy delays beyond patient factors may be potentially important to reduce risk of breast cancer recurrence and progression.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Tiempo de Tratamiento / Estadificación de Neoplasias Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Int J Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Tiempo de Tratamiento / Estadificación de Neoplasias Límite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Int J Cancer Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos